Trials / Completed
CompletedNCT01943045
Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM282 | |
| OTHER | Placebo |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-09-16
- Last updated
- 2015-11-17
Locations
9 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT01943045. Inclusion in this directory is not an endorsement.